Director's Message - New Hope for Treatment-Resistant Depression: Guessing Right on Ketamine

New Hope for Treatment-Resistant Depression: Guessing Right on Ketamine In this Director's message, Dr. Gordon discusses the role of NIMH and other researchers in the development of esketamine, an FDA-approved, rapid-acting medication that targets treatment-resistant depression. Read the Director's Message   NIMH Science News Questions? Contact NIMH! Director's Messages SUBSCRIBER SERVICES: Manage Preferences  |  Unsubscribe  |  Help This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Mental Health · 6001 Executive Boulevard · Bethesda, MD 20892-9663 · 1-866-615-6464